Cisplatin versus cisplatin plus etoposide in the treatment of advanced non-small-cell lung cancer. Lung Cancer Working Party, Belgium.
作者： J Klastersky , J P Sculier , G Bureau , P Libert , P Ravez
DOI: 10.1200/JCO.1989.7.8.1087
关键词:
摘要: We conducted a randomized study comparing the survival after treatment with cisplatin (120 mg/m2) or plus etoposide (100 mg/m2 on days 1, 2, and 3) in 162 evaluable patients advanced non-small-cell lung cancer (NSCLC). No statistically significant difference was detected; median 26 22 weeks, respectively, for receiving those etoposide. The objective response rate 19% 26% combination; corresponding rates were 17% 43% limited disease. differences detected between two arms as far toxicity concerned, except alopecia granulocytopenia, which occurred more frequently treated
ulb.ac.be
sci-hub.se 参考文章(16)
David R. Cox, Regression Models and Life-Tables Springer Series in Statistics. ,vol. 34, pp. 527- 541 ,(1992) , 10.1007/978-1-4612-4380-9_37
Jean Klastersky, E. Longeval, Robert De Jager, High-dose cisplatin with fluid and mannitol-induced diuresis in advanced lung cancer: A phase II clinical trial of the EORTC lung cancer working party (Belgium) Cancer treatment reports. ,vol. 64, pp. 1341- 1346 ,(1980)
E. L. Kaplan, Paul Meier, Nonparametric Estimation from Incomplete Observations Springer Series in Statistics. ,vol. 53, pp. 319- 337 ,(1992) , 10.1007/978-1-4612-4380-9_25
J.A Elliott, S Ahmedzai, D Hole, A.J Dorward, R.D Stevenson, S.B Kaye, S.W Banham, B.H.R Stack, K.C Calman, Vindesine and cisplatin combination chemotherapy compared with vindesine as a single agent in the management of non-small cell lung cancer: A randomized study European Journal of Cancer and Clinical Oncology. ,vol. 20, pp. 1025- 1032 ,(1984) , 10.1016/0277-5379(84)90104-4
Jean-Paul Sculier, Jean Klastersky, Progress in chemotherapy of non-small cell lung cancer European Journal of Cancer and Clinical Oncology. ,vol. 20, pp. 1329- 1333 ,(1984) , 10.1016/0277-5379(84)90049-X
Emile Longeval, Jean Klastersky, Combination chemotherapy with cisplatin and etoposide in bronchogenic squamous cell carcinoma and adenocarcinoma. A study by the EORTC lung cancer working party (Belgium) Cancer. ,vol. 50, pp. 2751- 2756 ,(1982) , 10.1002/1097-0142(19821215)50:12<2751::AID-CNCR2820501210>3.0.CO;2-3
R Peto, M C Pike, P Armitage, N E Breslow, D R Cox, S V Howard, N Mantel, K McPherson, J Peto, P G Smith, Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. British Journal of Cancer. ,vol. 35, pp. 1- 39 ,(1977) , 10.1038/BJC.1977.1
Stephen L. George, M.M. Desu, Planning the size and duration of a clinical trial studying the time to some critical event. Journal of Chronic Diseases. ,vol. 27, pp. 15- 24 ,(1974) , 10.1016/0021-9681(74)90004-6
RICHARD J. GRALLA, Cisplatin and Vindesine Combination Chemotherapy for Advanced Carcinoma of the Lung: A Randomized Trial Investigating Two Dosage Schedules Annals of Internal Medicine. ,vol. 95, pp. 414- 420 ,(1981) , 10.7326/0003-4819-95-4-414
J Klastersky, J P Sculier, P Ravez, P Libert, J Michel, G Vandermoten, P Rocmans, Y Bonduelle, M Mairesse, T Michiels, A randomized study comparing a high and a standard dose of cisplatin in combination with etoposide in the treatment of advanced non-small-cell lung carcinoma. Journal of Clinical Oncology. ,vol. 4, pp. 1780- 1786 ,(1986) , 10.1200/JCO.1986.4.12.1780